- The Myeloma Beacon - https://myelomabeacon.org -
IPH 2101 (anti-KIR)
By: Admin; Published: November 18, 2010 @ 4:50 pm | Comments Disabled
| Brand Name: | |
| Generic Name: | |
| Code Name: | IPH 2101 (anti-KIR) |
| Company: | Innate Pharma |
| FDA Clinical Phase: | 1/2 |
Description:
IPH 2101 is a human antibody that helps activate cells of the immune system to destroy cancer cells. Specifically, IPH 2101 activates anti-tumor immune cells, known as natural killer cells, by blocking KIR inhibitory receptors on the surface of the immune cells. IPH 2101 is being studied in patients with smoldering myeloma, multiple myeloma, and acute myeloid leukemia.
Clinical Trials:
For a list of clinical trials studying IPH 2101 for the treatment of multiple myeloma, see ClinicalTrials.gov [1].
Official website for IPH2101: http://www.innate-pharma.com/therapeutic-area/iph-2101 [2].
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2010/11/18/iph-2101/
URLs in this post:
[1] ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=IPH2101+myeloma&recr=Open
[2] http://www.innate-pharma.com/therapeutic-area/iph-2101: http://www.innate-pharma.com/therapeutic-area/iph-2101
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.